Drugs / KH617
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05667194 | Dec 2022 → Sep 2030 expected | cancer | Sichuan Honghe Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07138001 | Aug 2025 → Sep 2027 expected | glioblastoma | Sichuan Honghe Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KH617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05667194 ↗ |
| Route | Intravenous | “KH617： 33mg/kg intravenous infusion, every 4 weeks as one cycle.” NCT07138001 ↗ |